An observational study in Non-Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Completed at 1 site in Japan. Per ClinicalTrials.gov, last updated 2022-02-03.
Sponsored by Bristol-Myers Squibb · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb — 21 open to participants now, 35 under way, 10 of them phase 3. Carcinoma, Non-Small-Cell Lung · Bristol-Myers Squibb.
Among the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, this one is the 3rd largest by enrollment of the 21 observational ones that give a count, is one of 9 that started in 2017, is one of 21 observational ones, and was the 65th registered.
7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →21 of the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 9 more countries
Ages 18+
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 13 more countries
Ages 18+
RayzeBio, Inc. · Sites in Australia, New Zealand, South Africa
Ages 18+
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 29 more countries
Ages 18+
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 33 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 53 · Phase 3 29 · Phase 4 2
First in 2000; this study’s year is marked. 9 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 939 is above the median of 160 across 1,150 observational studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 169 across the 107 interventional studies, 404 across the 21 observational. Of the 91 that completed or were terminated, 47 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
6 of the studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06140836Phase 3Bristol-Myers SquibbA Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) | 2027-02-16 |
| NCT05161325Bristol-Myers SquibbA Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan | 2026-12-31 |
| NCT06946797Bristol-Myers SquibbA Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) | 2027-02-05 |
| NCT07671092RayzeBio, Inc.Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC | 2027-08 |
| NCT06544655Bristol-Myers SquibbA Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors | 2027-10-14 |
Add all 6 to your calendar (.ics) → With an account.
Among the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan
Previously treated advanced/metastatic NSCLC patients treated with nivolumab in Japan.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who meets the inclusion criteria will be included in the analysis to describe real-world clinical usage of nivolumab. However, patients treated with nivolumab falling in following criteria will be excluded for analysis for the other primary endpoint; overall effectiveness:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Initiated Nivolumab treatment at least once from 01 Apr. 2016 through 31 Dec. 2016
This study also gives Nivolumab. No intervention listed here names it: that was found by reading the record.
Description of clinical usage of nivolumab in previously treated NSCLC patients
Time frame: Approximately 9 months
Overall Survival (OS)
Measured from time of initial diagnosis and treatment with nivolumab until date of death
Time frame: Approximately 9 months
Progression Free Survival (PFS)
Time since index date (initial diagnosis and treatment with nivolumab) to either the first disease progression date or last known tumor assessment date, or death due to any cause, whichever occurs first
Time frame: Approximately 9 months
Percentage of patients receiving bi-weekly nivolumab
Time frame: Approximately 9 months
Percentage of patients receiving monotherapy or combination therapy
Time frame: Approximately 9 months
Percentage of patients receiving nivolumab as second or later line of therapy
Time frame: Approximately 9 months
Median treatment duration and range by line and histology
Time frame: Approximately 9 months
Rate of permanent and temporary discontinuations
Time frame: Approximately 9 months
Reasons for discontinuation of nivolumab
Time frame: Approximately 9 months
Reasons for re-challenge of nivolumab
Time frame: Approximately 9 months
Objective Response Rate (ORR) as assessed by investigator
ORR is defined as the number of participants with best overall response (OR) of confirmed complete response (CR) or partial response (PR) divided by the total number of participants who received treatment
Time frame: Approximately 9 months
Ran from Apr 2017 to primary completion in Dec 2017, 8 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →